KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBT Margin (2016 - 2025)

Historic EBT Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 0.8%.

  • Jazz Pharmaceuticals' EBT Margin fell 182300.0% to 0.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.04%, marking a year-over-year decrease of 220200.0%. This contributed to the annual value of 11.56% for FY2024, which is 37900.0% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported EBT Margin of 0.8% as of Q3 2025, which was down 182300.0% from 70.34% recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' EBT Margin ranged from a high of 22.33% in Q1 2021 and a low of 70.34% during Q2 2025
  • For the 5-year period, Jazz Pharmaceuticals' EBT Margin averaged around 2.28%, with its median value being 1.53% (2022).
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 614700bps in 2021, then plummeted by -838100bps in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' EBT Margin (Quarter) stood at 5.0% in 2021, then crashed by -600bps to 34.97% in 2022, then soared by 117bps to 6.08% in 2023, then skyrocketed by 101bps to 12.24% in 2024, then tumbled by -93bps to 0.8% in 2025.
  • Its EBT Margin stands at 0.8% for Q3 2025, versus 70.34% for Q2 2025 and 12.24% for Q4 2024.